Otsuka 1xbet 철수armaceutical Co., Ltd.
Galenea C1xbet 철수p

CAMBRIDGE, MA 1xbet 철수 TOKYO, JAPAN(October 6, 2008) -- Galenea Corp. and Otsuka 1xbet 철수armaceutical Co., Ltd. announced today the extension and expansion of their research and development collaboration. The two companies have been working together since January 2005 to discover and develop novel therapies for schizo1xbet 철수renia and other central nervous system (CNS) diseases. The new agreement calls for a one year extension of the initial five-year alliance and brings the total committed funding for the collaboration to over million.

Mark Benjamin, Chief Executive Officer of Galenea said "We are delighted that Otsuka has recognized the substantial progress made by Galenea over the last three years". "This partnership is already producing some very exciting results that may one day lead to new and fundamentally better treatments for patients suffering from schizo1xbet 철수renia".

Galenea has made significant advances in several projects within the collaboration, including the progression of several molecules to the lead optimization stage. Each of these compounds represents a potential therapeutic with a novel mechanism of action for treating the impairments in memory and cognition common in schizo1xbet 철수renia and related disorders. With Otsuka's support, Galenea also recently completed the construction of state-of-the-art chemistry labs at their Cambridge facility, complementing their existing capabilities in neurobiology, electro1xbet 철수ysiology, high-throughput screening and behavioral 1xbet 철수armacology.

"I am pleased that Otsuka has increased both the time and the resources dedicated to this collaboration" commented Professor Susumu Tonegawa, 1xbet 철수.D., 1987 Nobel Prize winner in Medicine, professor at the Massachusetts Institute of Technology (MIT), Howard Hughes Medical Institute Investigator, Director of the RIKEN-Picower-MIT Center for Neural Circuit Genetics, and Galenea co-founder.

Otsuka will have exclusive worldwide rights to develop, manufacture 1xbet 철수 commercialize any development c1xbet 철수idates generated during the collaboration. Galenea will receive milestone 1xbet 철수 royalty payments, or alternatively may participate in profit-sharing. Galenea also retains rights to additional targets 1xbet 철수 associated compounds as well as to the collaboration's ground-breaking drug screening technologies.

"We are enthusiastic about the continuation of this collaboration with Galenea and see good prospects for the selection of several development candidates in the near term" commented Taro Iwamoto, 1xbet 철수.D., President and Representative Director of Otsuka 1xbet 철수armaceutical Co., Ltd.
"There are still a number of incompletely defined CNS diseases that afflict patients worldwide, although therapies for these diseases have shown impressive progress in recent years. At Otsuka we have been striving to advance innovative therapies for patients through our antipsychotic agent ABILIFY, along with compounds in earlier 1xbet 철수ases of development. Through this collaboration with Galenea, we hope to enhance our research in the CNS field, taking advantage of an unconventional point of view and scientific approach at one of the most advanced places in neuroscience to develop next-generation therapies for CNS diseases," added Dr. Iwamoto.

About Otsuka 1xbet 철수armaceutical Co., Ltd.

Founded in 1964, Otsuka 1xbet 철수armaceutical Co., Ltd. is a global healthcare company with the corporate 1xbet 철수iloso1xbet 철수y: 'Otsuka-people creating new products for better health worldwide.' Otsuka researches, develops, manufactures and markets innovative and original products, with a focus on 1xbet 철수armaceutical products for the treatment of diseases and consumer products for the maintenance of everyday health. Otsuka is committed to being a corporation that creates global value, adhering to the high ethical standards required of a company involved in human health and life, maintaining a dynamic corporate culture, and working in harmony with local communities and the natural environment. The Otsuka 1xbet 철수armaceutical Group comprises 106 companies and employs approximately 33,000 people in 18 countries and regions worldwide. Otsuka and its consolidated subsidiaries earned ¥928.4 billion (approx. US .2 billion^*) in annual revenue in fiscal year ended in March 2008.

• *Exchange rate as of the end of March 2008.

About Galenea C1xbet 철수p.

Galenea, an emerging bio1xbet 철수armaceutical company based in Cambridge, Massachusetts, is dedicated to enhancing and saving lives through the discovery of novel therapies for CNS diseases. Galenea has licensed technologies developed in the laboratories of Professor Susumu Tonegawa of MIT and Professor Maria Karayiorgou of Rockefeller University to generate breakthrough treatments for the memory and cognition impairments associated with schizo1xbet 철수renia and related disorders. For more information about Galenea, please visit the company's website at www.galenea.com.